Theradiag Competitors and Similar CompaniesClear all

Theradiag's competitors and similar companies include Cibic, Yashraj Biotechnology, BBI Solutions and Viracor Eurofins.

	Theradiag Theradiag is a company specializing in in vitro diagnostics and theranostics, with a focus on autoimmune diseases and biotherapy monitoring.	Cibic Cibic is a clinical biochemistry laboratory.	Yashraj Biotechnology Yashraj Biotechnology is a company that supplies diagnostic products.	BBI Solutions BBI Solutions is a company that develops and manufactures immuno-diagnostics reagents.	Viracor Eurofins Viracor Eurofins is a company operating as a specialty lab that provides infectious disease, allergy, and immunology testing.
Founding Date	Founding Date 1990	Founding Date 1990	Founding Date 1999	Founding Date 1986	Founding Date N/A
Type	Type Subsidiary	Type Private	Type Private	Type Private	Type Subsidiary
Tags	Tags Healthcare biotech medical diagnostics	Tags Healthcare biotech medical diagnostics	Tags Healthcare biotech medical diagnostics	Tags Healthcare biotech medical diagnostics	Tags Healthcare biotech medical diagnostics
Locations	Locations Croissy-Beaubourg, FR HQ	Locations Rosario, AR HQ	Locations Navi Mumbai, IN HQ Berlin, DE Navi Mumbai, IN San Diego, US	Locations Crumlin, GB HQ Freiburg Im Breisgau, DE Cape Town, ZA Edinburgh, GB Porton Down, GB Sittingbourne, GB see more	Locations Lee's Summit, US HQ
Employees	Employees 602% increase	Employees 3161% decrease	Employees 2531% increase	Employees 3491% increase	Employees 2572% decrease
Financial
Revenue (est.)	Revenue (est.) €12.2m (FY, 2022)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £55.5m (FY, 2020)	Revenue (est.) N/A
Cost of goods	Cost of goods €3.5m (FY, 2022)	Cost of goods N/A	Cost of goods N/A	Cost of goods £25.4m (FY, 2020)	Cost of goods N/A
Gross profit	Gross profit €8.8m (FY, 2022)	Gross profit N/A	Gross profit N/A	Gross profit £30.1m (FY, 2020)	Gross profit N/A
Net income	Net income (€487k) (FY, 2022)	Net income N/A	Net income N/A	Net income (£9.9m) (FY, 2020)	Net income N/A